Navigation Links
Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
Date:6/6/2009

the FDA may not agree with Orexigen's interpretation of efficacy and safety results; earlier clinical trials may not be predictive of future results; Contrave or Empatic may not receive regulatory approval on a timely basis or at all, and the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave or Empatic to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave or Empatic, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
2. Orexigen(R) Therapeutics to Present at Upcoming Meetings
3. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
4. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
5. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
6. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
7. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... 2014 Calcivis, a medical ... tooth decay, today announces that it has completed ... Activity Imaging System. The Calcivis Caries ... and consumable combination designed to transform the assessment ... involves a unique, proprietary bioluminescence approach combined with ...
(Date:11/26/2014)... November 26, 2014 The North ... segments the market for detailed analysis of the ... market to reach $616.3 million by 2018, growing ... 2018. , Browse through the TOC of the ... get an idea of the in-depth analysis and ...
(Date:11/26/2014)... November 26, 2014 On January, 14, ... Baltimore and Washington D.C. science community to the UMBC ... event, sponsored by the Protein Society, will take place ... Center, Room 312. Through discussion, presentations and workshops, ... importance of proteins, their role in the industry and ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 Silicon Valley ... forces with RPM Alliance , provider of clinical ... companies. With the latest addition to its CRO Partnership ... validated EDC system to India. , “We have ... robust and customizable EDC platform which is both user ...
Breaking Biology Technology:Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2
... , REDWOOD CITY, Calif. , June 17 ... today announced a global strategic alliance to discover, develop and commercialize ... stem cells are a subset of tumor cells believed to play ...   , , , ...
... at Rensselaer Polytechnic Institute have developed a new, ... measure only billionths of a meter thick. The ... on nearly any surface including silicon wafers, could ... Sang-Kee Eah, assistant professor in the Department ...
... ... ability to study the functional relevance of a drug treatment on the heart following ... , ... 2010 -- MD Biosciences , a Preclinical Contract Research Organization (CRO), offers in ...
Cached Biology Technology:OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 2OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 3OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 4OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 5Researchers develop ultra-simple method for creating nanoscale gold coatings 2MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury 2
(Date:11/5/2014)... diversity in their ability to identify scents and odors. ... their perceptual evaluation of odors, with women outperforming men ... Sex differences in olfactory detection may play a role ... one,s perception of smell, which is naturally linked to ... been suggested to be cognitive or emotional, rather than ...
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
(Date:11/3/2014)... study published in this month,s Proceedings ... activity of a recently discovered communication molecule of the ... been known to limit inflammation and the current study ... inhibits the ability of the immune system to recognize ... underlies IL-37,s effect on the immune system now allows ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... can do more than just make you feel hot, reports ... Chemistry ; the active chemical in peppers can directly induce ... Capsaicin is the chemical in chili peppers that ... sensory neurons, creating the heat sensation and subsequent reactions like ...
... of York have helped to reveal more about the way ... could help in the development of new treatments for serious ... studied the way a protein found on the surface of ... fibronectin. Their discovery is an important step in understanding how ...
... Dr. Eric Lazartigues, Assistant Professor of Pharmacology at LSU ... been awarded a $1.2 million Research Project (RO1) grant ... the National Institutes of Health. The 5-year grant will ... role of the brain in regulating blood pressure and ...
Cached Biology News:LSUHSC's Lazartigues awarded $1.2 million grant 2